An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Status:	Enrolling by invitation
Conditions:	Breast Cancer, Lung Cancer, Colorectal Cancer, Cancer, Cancer, Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	12/16/2018
Start Date:	November 2016
End Date:	November 2019

An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib
plus background cancer therapy, or background cancer therapy alone to subjects from an
Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been
terminated.

This study will also provide another mechanism for reporting adverse events related to study
drug safety.

Inclusion Criteria:

- Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of
ruxolitinib that has completed or been terminated.

- Currently tolerating treatment in the parent protocol.

- Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus
background cancer therapy, or background cancer therapy alone, as determined by the
investigator.

- Have at least stable disease, as determined by the investigator.

- Has demonstrated compliance, as assessed by the investigator, with the parent study
protocol requirements.

Exclusion Criteria:

- Has been permanently discontinued from study treatment in the parent study for any
reason.

- Able to access ruxolitinib and/or background cancer therapy outside of the clinical
study.

We found this trial at

sites

U of Texas M.D. Anderson Cancer Center

Houston, Texas 77030

from

Houston, TX